Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors

NCT06993844 is registered in ClinicalTrials.gov with Ensem Therapeutics as lead sponsor.

NCT NCT06993844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06993844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ETX-636, a Pan-mutant-selective PI3Kα Inhibitor, as Monotherapy and in Combination With Other Anticancer Therapies in Participants With Advanced Solid Tumors
Lead sponsor
Ensem Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 10, 2025
Completion date
December 30, 2027
Enrollment
233 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced solid tumors